27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Aptorum Group Limited (NASDAQ: APM) has completed two initial cohorts of the single-dose ascending dose (SAD) portion of the Phase 1 trial evaluating ALS-4 small molecule targeting Staphylococcus aureus.
- Total 6 cohorts for SAD and three cohorts for multiple ascending doses (MAD) have been planned.
- Dosing and safety reviews of Cohort A (25mg) and Cohort B (50mg) have been completed. No human subjects were dropped out of the studies, and there were no Serious Adverse Events observed.
- In addition, no relevant clinical changes regarding vital signs, ECG, clinical laboratory test results, and physical examinations were observed compared to the relevant baseline.
- Cohort C (100mg) studies have been initiated.
- The company also completed the Pre-IND meeting with the FDA related to SACT-1, a repurposed small molecule targeting neuroblastoma.
- SACT-1 is on track to start clinical studies in Q3 of 2021.
- Price Action: APM shares are up 32.4% at $3.15 on the last check Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!